The Platelet as a Peripheral Model of Serotonergic Function in Child Psychiatry

  • Moshe Rehavi
  • Ronit Weizman

Abstract

Neurochemical strategies have been adopted to implicate specific neurotransmitters in psychiatric disorders and the therapeutic mechanisms of psychotropic agents. These studies have examined alterations in neurotransmitter metabolites in urine, plasma, and spinal fluid as a reflection of the release and turnover of specific neurotransmitters in the brain (a marker of presynaptic function), and binding to specific receptor sites (a marker of postsynaptic function). With the introduction of positron-emission tomography (PET), it has become feasible to evaluate the distribution and density of at least some neurotransmitter receptors in vivo in patients and healthy normal control subjects. Another strategy has involved the identification of specific neurotransmitter and psychotropic drug receptor sites on easily accessible peripheral tissues. A major limitation of these latter studies is the assumption that the binding characteristics of these “peripheral” binding sites reflects the situation in brain accurately.

Keywords

Depression Schizophrenia Serotonin Histamine Clonidine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Glowinski, J, Axelrod J : Inhibition of uptake of tritiated-noradrenaline in the intact rat brain by imipramine and structually related compounds. Nature (Lond) 204:1318–1319, 1964CrossRefGoogle Scholar
  2. 2.
    Iversen LL : Uptake mechanism for neurotransmitter amines. Biochem Pharmacol 23:1927–1935, 1974PubMedCrossRefGoogle Scholar
  3. 3.
    Carlsson A, Corrodi H, Fuxe K, et al : Effect of antidepressant drugs on the depletion of intraneuronal brain 5-hydroxytryptamine stores caused by 4-methyl-alpha-ethyl-meta tyramine. Eur J Pharmacol 5:357–366, 1969PubMedCrossRefGoogle Scholar
  4. 4.
    Sulser F, Vetulani J, Hobley PL : Mode of action of antidepressant drugs. Biochem Pharmacol 27:257–261, 1978PubMedCrossRefGoogle Scholar
  5. 5.
    Banerjee SP, Kung LS, Riggs SJ, et al : Development of (β-adrenergic receptor subsensitivity by antidepressants. Nature (Lond) 268:455–456, 1977CrossRefGoogle Scholar
  6. 6.
    Wolfe BB, Harden TK, Spom JR, et al : Presynaptic modulation of β-adrenergic receptors in rat cerebral cortex after treatment with antidepressants. J Pharmacol Exp Ther 207:446–457, 1978PubMedGoogle Scholar
  7. 7.
    Peroutka SJ, Synder SH : Long-term antidepressant treatment decreases spirperidol-labeled serotonin receptor binding. Science 210:88–90, 1980PubMedCrossRefGoogle Scholar
  8. 8.
    Rehavi M, Maayani S, Sokolovsky M : Tricyclic antidepressants as antimuscarinic drugs: In vivo and in vitro studies. Biochem Pharmacol 26:1559–1567, 1977PubMedCrossRefGoogle Scholar
  9. 9.
    Synder SH, Yamamura HI : Antidepressants and the muscarinic acetylcholine receptor. Arch Gen Psychiatry 34:236–239, 1977CrossRefGoogle Scholar
  10. 10.
    Green JP, Maayani S : Tricyclic antidepressants block histamine H2 receptor in brain. Nature (Lond) 269:163–165, 1977CrossRefGoogle Scholar
  11. 11.
    Peroutka SJ, Synder SH : [3H]-Mianserin: Differential labeling of serotonin2 and histamine receptors in rat brain. J Pharmacol Exp Ther 216:142–148, 1981PubMedGoogle Scholar
  12. 12.
    U’Prichard DC, Greenberg DA, Sheehan PPet al: Tricyclic antidepressants: Therapeutic properties and affinity for a-noradrenergic receptor binding sites in the brain. Science 199:197–198, 1978PubMedCrossRefGoogle Scholar
  13. 13.
    Bennett JL, Aghajanian GK : D-LSD binding to brain homogenates: Possible relationship to serotonin receptors. Life Sci 15:1935–1944, 1975CrossRefGoogle Scholar
  14. 14.
    Raisman R, Briley M, Langer SZ : Specific tricyclic antidepressant binding sites in rat brain. Nature (Lond) 281:148–150, 1979CrossRefGoogle Scholar
  15. 15.
    Raisman R, Briley, M, Langer SZ : Specific tricyclic antidepressant binding sites in rat brain characterized by high affinity [3H]imipramine binding. Eur J Pharmacol 61:373–380, 1980PubMedCrossRefGoogle Scholar
  16. 16.
    Briley M, Raisman R, Langer SZ : Human platelets possess high affinity binding sites for [3H]imipramine. Eur J Pharmacol 58:347–348, 1979PubMedCrossRefGoogle Scholar
  17. 17.
    Paul SM, Rehavi M, Skolnick P, et al : Demonstration of specific high affinity binding sites for [3H]imipramine on human platelets. Life Sci 26:953–959, 1980PubMedCrossRefGoogle Scholar
  18. 18.
    Langer SZ, Briley M, Raisman R, et al : Specific [3H]imipramine binding in human platelets. Naunyn-Schmiedebergs Arch Pharmacol 313:189–194, 1980PubMedCrossRefGoogle Scholar
  19. 19.
    Paul SM, Rehavi M, Rice KC, et al: Does high affinity [3H]imipramine binding label serotonin reuptake sites in brain and platelet? Life Sci 28:2753–2760, 1981PubMedCrossRefGoogle Scholar
  20. 20.
    Pletscher A : Metabolism, transfer and storage of 5HT in blood platelets. Br J Pharmacol 32:1–16, 1968Google Scholar
  21. 21.
    Sneddon JM : Blood platelets as a model for monoamine-containing neurons. Prog Neurobiol 1:151–198, 1973PubMedCrossRefGoogle Scholar
  22. 22.
    Stahl SM : The human platelet: A diagnostic and research tool for the study of biogenic amines in psychiatric and neurologic disorders. Arch Gen Psychiatry 34:509–516, 1977PubMedCrossRefGoogle Scholar
  23. 23.
    Langer SZ, Agid FJ, Raisman R et al : Distribution of specific high-affinity binding sites for [3H]imipramine in human brain. J Neurochem 37:267–271, 1981PubMedCrossRefGoogle Scholar
  24. 24.
    Palkovitz M, Raisman R, Briley M, et al : Regional distribution of [3H]imipramine binding in rat brain. Brain Res 210:493–498, 1981CrossRefGoogle Scholar
  25. 25.
    Rehavi M, Paul SM, Skolnick P, et al : Demonstration of specific high affinity binding sites for [3H]imipramine in human brain. Life Sci 26:2273–2279, 1980PubMedCrossRefGoogle Scholar
  26. 26.
    Reith ME A, Sershen H, Allen D, et al : High and low affinity of [3H] imipramine in mouse cerebral cortex. J Neurochem 40:389–392, 1983PubMedCrossRefGoogle Scholar
  27. 27.
    Langer SZ, Moret C, Raisman R, et al : High affinity [3H]imipramine binding in rat hypothalamus. Association with uptake of serotonin but not of norepinephrine. Science 210:1133–1135, 1980PubMedCrossRefGoogle Scholar
  28. 28.
    Briley M, Raisman R, Arbilla S, et al : Concommittant decrease in [3H]imipramine binding in cat brain and platelets after chronic treatment with imipramine. Eur J Pharmacol 81:309–314, 1982PubMedCrossRefGoogle Scholar
  29. 29.
    DeParda M, Pieri L, Keller H, et al : Effects of 5,6-dihydroxytryptamine and 5,7-dihydroxytryptamine on rat central nervous system after intraventricular or intracerebral application and on blood platelets in vitro. Ann NY Acad Sci 305:595–603, 1978CrossRefGoogle Scholar
  30. 30.
    Dumbrille-Ross A, Tang SW : Absence of high-affinity [3H]imipramine binding in platlets and cerebral cortex of Fawn-Hooded rats. Eur J Pharmacol 72:137–138, 1981PubMedCrossRefGoogle Scholar
  31. 31.
    Mocchetti I, Brunello N, Racagni G : Ontogenetic study of [3H]imipramine binding sites and serotonine uptake system: Indication of possible interdependence. Eur J Pharmacol 83:151–154, 1982PubMedCrossRefGoogle Scholar
  32. 32.
    Sette M, Raisman R, Briley M, et al : Localization of tricyclic antidepressant binding sites on serotonin nerve terminals. J Neurochem 37:40–42, 1981PubMedCrossRefGoogle Scholar
  33. 33.
    Gross G, Gothert M, Ender HP, et al : [3H]imipramine binding sites in the rat brain selective localization on serotonergic neurons. Naunyn-Schmiedebergs Arch Pharmacol 317:310–314, 1981PubMedCrossRefGoogle Scholar
  34. 34.
    Brunello J, Chaung DM, Costa E : Different synaptic location of mianserin and imipramine binding sites. Science 215:1112–1115, 1982PubMedCrossRefGoogle Scholar
  35. 35.
    Rehavi M, Ittah Y, Rice KC, et al : 2-Nitroimipramine: A selective irreversible inhibitor of [3H]serotonin uptake and [3H]imipramine binding in platelets. Biochem Biophys Res Commun 99:954–959, 1981PubMedCrossRefGoogle Scholar
  36. 36.
    Rehavi M, Ittah Y, Skolnick P, et al : Nitroimipramines-synthesis and pharmacological effects of potent long-acting inhibitors of [3H]serotonin uptake and [3H]imipramine binding. Naunyn-Schmiedebergs Arch Pharmacol 320:45–49, 1982PubMedCrossRefGoogle Scholar
  37. 37.
    Rehavi M, Tracer H, Rice KC, et al : [3H]2-Nitroimipramine: A selective “slowly-dissociating” probe of the imipramine binding site ( “serotonin transporter”) in platelets and brain. Life Sci 32:645–653, 1983PubMedCrossRefGoogle Scholar
  38. 38.
    Dawson TM, Wamsley JK : Autoradiographic localization of [3H]imipramine binding sites: Association with serotonergic neurons. Brain Res Bull 11:325–329, 1983PubMedCrossRefGoogle Scholar
  39. 39.
    Biegon A, Rainbow TC : Distribution of imipramine binding sites in the rat brain studied by quantitative autoradiography. Neurosci Lett 37:209–214, 1983PubMedCrossRefGoogle Scholar
  40. 40.
    Rudnick G : Active transport of 5-hydroxytryptamine by plasma membrane vescicles isolated from human blood platelets. J Biol Chem 252:2170–2174, 1977PubMedGoogle Scholar
  41. 41.
    Briley M, Langer SZ : Sodium dependency of [3H]imipramine binding in rat cerebral cortex. Eur J Pharmacol 72:377–380, 1981PubMedCrossRefGoogle Scholar
  42. 42.
    Lingjaerde D: Blood platelets: As a model system for studying the biochemistry of depression, in Usdin E (ed): Frontiers in Biochemical and Pharmacological Research in Depression. New York, Raven, pp 99-111Google Scholar
  43. 43.
    Kinnier WJ, Chang DM, Gwynn G, et al : Characteristics and regulation of high affinity [3H]imipramine binding to rat hippocampal membranes. Neuropharmacology 20:411–419, 1981PubMedCrossRefGoogle Scholar
  44. 44.
    Rehavi M, Skolnick P, Paul SM : Subcellular distribution of high affinity [3H]imipramine binding and [3H]serotonin uptake in rat brain. Eur J Pharmacol 87:335–339, 1983PubMedCrossRefGoogle Scholar
  45. 45.
    Sette M, Briley MS, Langer SZ : Complex inhibition of [3H]imipramine binding by serotonin and nontricyclic serotonin uptake blockers. J Neurochem 40:622–628, 1983PubMedCrossRefGoogle Scholar
  46. 46.
    Wennogle LP, Meyerson LR : Serotonin uptake inhibitors differentially modulate high affinity imipramine dissociation in human platelet membranes. Life Sci 361:1541–1550, 1985CrossRefGoogle Scholar
  47. 47.
    Segonzac A, Schoemaker A, Langer SZ : Temperature dependence of drug interaction with the platelet 5-hydroxytryptamine transporter. J Neurochem 48:331–339, 1987PubMedCrossRefGoogle Scholar
  48. 48.
    Briley MS, Langer SZ, Raisman R, et al : Tritiated imipramine binding sites are decreased in platelets of untreated depressed patients. Science 209:303–305, 1980PubMedCrossRefGoogle Scholar
  49. 49.
    Asrach KB, Shin JC, Kulcsar A : Decreased [3H]imipramine binding in depressed male and females. Common Psychopharmacol 4:425–432, 1980Google Scholar
  50. 50.
    Paul SM, Rahavi M, Skolnick P, et al: Depressed patients have decreased binding of tritiated imipramine to platelet serotonin “transporter.” Arch Gen Psychiatry 38:1315–1317, 1981PubMedCrossRefGoogle Scholar
  51. 51.
    Raisman, R, Sechter, D, Briley, MS, et al : High affinity [3H]imipramine binding to platelets from untreated and treated depressed patients compared to healthy volunteers. Psychopharmacology 75:368–371, 1981PubMedCrossRefGoogle Scholar
  52. 52.
    Raisman R, Briley MS, Bouchami F, et al : [3H]imipramine binding and serotonin uptake in platelets from untreated depressed patients and control volunteers. Psychopharmacology 77:332–335, 1982PubMedCrossRefGoogle Scholar
  53. 53.
    Suranyi-Cadotte BE, Wood PL, Nair NPV, et al : Normalization of platelet [3H]imipramine binding in depressed patients during remission. Eur J Pharmacol 85:357–358, 1982PubMedCrossRefGoogle Scholar
  54. 54.
    Suranyi-Cadotte BE, Wood PL, Schwartz G, et al : Altered platelet [3H]imipramine binding in schizoaffective and depressive disorders. Biol Psychiatry 18:923–927, 1983PubMedGoogle Scholar
  55. 55.
    Wagner A, Aberg-Wistedt A, Asberg M, et al : Lower [3H]imipramine binding in platelets from untreated depressed patients compared to healthy controls. Psychiatry Res 16:131–139, 1985PubMedCrossRefGoogle Scholar
  56. 56.
    Langer SZ, Galzin AM, Poirier MF, et al : Association of [3H]imipramine and [3H]paroexetine binding with the 5HT transporter in brain and platelets: relevance to studies in depression. J Receptor Res 7:499–521, 1987Google Scholar
  57. 57.
    Roy A, Everett D, Pickar D, et al : Platelet tritiated imipramine binding and serotonin uptake in depressed patients and controls. Arch Gen Psychiatry 44:320–327, 1987PubMedCrossRefGoogle Scholar
  58. 58.
    Baron M, Barkai A, Gruen R, et al : [3H]imipramine platelet binding sites in unipolar depression. Biol Psychiatry 18:1403–1409, 1983PubMedGoogle Scholar
  59. 59.
    Whitaker PM, Warsh JJ, Stancer HC, et al : Seasonal variation in platelet [3H]imipramine bindings: Comparable values in control and depressed populations. Psychiatry Res 11:127–131, 1984PubMedCrossRefGoogle Scholar
  60. 60.
    Muscettola G, DiLauro A, Giannini C : Platelet [3H]imipramine binding in bipolar patients. Psychiatry Res 18:343–353, 1986PubMedCrossRefGoogle Scholar
  61. 61.
    Mellrup ET, Plenge P, Rosenberg R : [3H]Imipramine binding sites in platelets from psychiatric patients. Psychiatry Res 7:221–227, 1982CrossRefGoogle Scholar
  62. 62.
    Wirz-Justice A, Krauchie K, Morimasa T, et al : Circadian rhythm of [3H]imipramine binding in the rat suprachiamatic nuclei. Eur J Pharmacol 87:331–333, 1983PubMedCrossRefGoogle Scholar
  63. 63.
    Egrise D, Desmedt D, Schoutens A, et al : Circannual variations in the density of tritiated imipramine binding sites on blood platelets in man. Neuropsychobiology 10:101–102, 1983PubMedCrossRefGoogle Scholar
  64. 64.
    Gulzin AM, Loo H, Sechter D, et al : Lack of seasonal variation in platelet [3H]imipramine binding in humans. Biol Psychiatry 21:876–882, 1986CrossRefGoogle Scholar
  65. 65.
    Stanley M, Virgilio J, Gershon S: Tritiated imipramine binding sites are decreased in the frontal cortex of suicides. Science 216:137–139, 1982CrossRefGoogle Scholar
  66. 66.
    Kinnier WJ, Chang DM, Gwynn G, et al : Down regulation of dihydroalprenolol and imipramine binding sites in brain of rats repeatedly treated with imipramine. Eur J Pharmacol 67:289–294, 1980PubMedCrossRefGoogle Scholar
  67. 67.
    Mogilnicka E, Arbilla S, Depoortere H, et al : Rapid eye movement sleep deprivation decreases the density of [3H]dihydroalprenolol and [3H]imipramine binding sites in the rat cerebral cortex. Eur J Pharmacol 65:289–293, 1980PubMedCrossRefGoogle Scholar
  68. 68.
    Plenge P, Mellrup ET : [3H]imipramine high-affinity binding sites in rat brain. Effects of imipramine and lithium. Psychopharmacology 77:94–97, 1982PubMedCrossRefGoogle Scholar
  69. 69.
    Langer SZ, Zarifian E, Briley M, et al : High affinity [3H]imipramine binding in: a new biological marker in depression. Pharmacopsychiatry 15:4–10, 1982CrossRefGoogle Scholar
  70. 70.
    Kupfer D : REM latency: A psychobiologic marker for primary depressive disease. Biol Psychiatry 11:159–174, 1976PubMedGoogle Scholar
  71. 71.
    King D : Pathologic and therapeutic consequences of sleep loss: A review. Dis Nerv Syst 38:843–879, 1977Google Scholar
  72. 72.
    Poirier M-F, Benkelfat C, Loo H, et al : Reduced Bmax of [3H]imipramine binding to platelets of depressed patients free of previous medication with 5HT uptake inhibitors. Psychopharmacology 89:456–461, 1986PubMedCrossRefGoogle Scholar
  73. 73.
    Lewis DA, McChesney C : Tritiated imipramine binding distinguishes among subtypes of depression. Arch Gen Psychiatry 42:485–488, 1985PubMedCrossRefGoogle Scholar
  74. 74.
    Severson JA, Marcusson JO, Osterburg HH, et al : Elevated density of [3H]imipramine binding in aged human brain. J Neurochem 45:1382–1389, 1985PubMedCrossRefGoogle Scholar
  75. 75.
    Severson JA : [3H]imipramine binding in aged mouse brain: Regulation by ions and serotonin. Neurobiol Aging 7:83–87, 1986PubMedCrossRefGoogle Scholar
  76. 76.
    Brunello N, Riva M, Volterra A, et al : Aged-related changes in 5HT uptake and [3H]imipramine binding sites in rat cerebral cortex. Eur J Pharmacol 110:393–394, 1985PubMedCrossRefGoogle Scholar
  77. 77.
    Schneider LS, Severson JA, Sloane RB : Platelet [3H]imipramine binding in depressed elderly patients. Biol Psychiatry 20:1232–1234, 1985CrossRefGoogle Scholar
  78. 78.
    Hrdina PD, Lapierre YD, Horn ER, et al : Platelet [3H]imipramine binding: A possible predictor of response to antidepressant treatment. Prog Neuropsychopharmacol Biol Psychiatry 9:619–623, 1985PubMedCrossRefGoogle Scholar
  79. 79.
    Tanimoto K, Maeda K, Terada T : Alteration of platelet [3H]imipramine binding in mildly depressed patients correlates with disease severity. Biol Psychiatry 20:340–343, 1985PubMedCrossRefGoogle Scholar
  80. 80.
    Rehavi M, Weizman R, Carel C, et al : High affinity [3H]imipramine binding in platelets of children and adolescents with major affective disorders. Psychiatry Res 13:31–39, 1984PubMedCrossRefGoogle Scholar
  81. 81.
    Puig-Antich J, Gittelman R : Depression in childhood and adolescence, in Paykel ES (ed): Handbook of Affective Disorders. London, Churchill, 1981, p. 379–390.Google Scholar
  82. 82.
    Puig-Antich J : Neuroendocrine and sleep correlates of prepubertal major depressive disorder: Current status of the evidence, in Cantwell DP Carlson GA(eds): Affective Disorders in Childhood and Adolescence: An Update. New York, Spectrum Publications, 1983, p 211–220.Google Scholar
  83. 83.
    Geller B, Rogol AD, Knitter EF : Preliminary data on the dexamethasone suppression test in children with major depressive disorder. Am J Psychiatry 140:620–623, 1983PubMedGoogle Scholar
  84. 84.
    Targum SD, Kapodanno AE : The dexamethasone suppression test in adolescent psychiatric inpatients. Am J Psychiatry 140:589–591, 1983PubMedGoogle Scholar
  85. 85.
    Yaryura-Tobias JA, Bhagavan HN : L-Tryptophan in obsessive-compulsive disorders. Am J Psychiatry 134:1298–1299, 1977PubMedGoogle Scholar
  86. 86.
    Insel TR, Murphy DL, Cohen RM, et al : Obsessive-compulsive disorder: A double blind trial of cloimipramine and clorgyline. Arch Gen Psychiatry 40:605–612, 1983PubMedCrossRefGoogle Scholar
  87. 87.
    Flament MF, Rapport JL, Berg CJ, et al : Cloimipramine treatment of childhood obsessive-compulsive disorder. Arch Gen Psychiatry 42:977–983, 1985PubMedCrossRefGoogle Scholar
  88. 88.
    Thoren P, Asberg A, Cronholm B, et al : Chlorimipramine treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 37:1281–1285, 1980PubMedCrossRefGoogle Scholar
  89. 89.
    Flament MF, Rapoport JL, Murphy DL, et al : Biochemical changes during clomipramine treatment of childhood obsessive-compulsive disorder. Arch Gen Psychiatry 44:219–225, 1987PubMedCrossRefGoogle Scholar
  90. 90.
    Insel TR, Kalin N, Guttmacher LB, et al : The dexamethasone suppression test in patients with primary obsessive-compulsive disorder. Psychiatry Res 6:153–160, 1980CrossRefGoogle Scholar
  91. 91.
    Rapoport J, Elkins R, Langer DH, et al : Childhood obsessive-compulsive disorder. Am J Psychiatry 138:1545–1554, 1981PubMedGoogle Scholar
  92. 92.
    Insel TR, Gillin C, Moore A, et al : The sleep of patients with obsessive compulsive disorder. Arch Gen Psychiatry 39:1372–1377, 1982PubMedCrossRefGoogle Scholar
  93. 93.
    Siever LJ, Insel TR, Jimerson DC, et al : Growth hormone response to cloidine in obsessive-compulsive patients. Br J Psychiatry 39:1372–1377, 1982Google Scholar
  94. 94.
    Insel TR, Mueller EA, Gillin C : Biological markers in obsessive-compulsive and affective disorders. J Psychiatr Res 18:407–423, 1984PubMedCrossRefGoogle Scholar
  95. 95.
    Stem RS, Marks IM, Mawson D : Cloimipramine and exposure for compulsive rituals. Plasma levels, side effects, and outcome. Br J Psychiatry 136:161–166, 1980CrossRefGoogle Scholar
  96. 96.
    Weizman A, Carmi M, Hermesh H, et al : High affinity imipramine binding and serotonin uptake in platelets of eight adolescent and ten adult obsessive-compulsive patients. Am J Psychiatry 143:335–339, 1986PubMedGoogle Scholar
  97. 97.
    Insel TR, Mueller EA, Alterman I, et al: Obsessive-compulsive disorder and serotonin: Is there a connection? Biol Psychiatry 20:1174–1188, 1985PubMedCrossRefGoogle Scholar
  98. 98.
    Weizman A, Weizman R, Szekely GA, et al : Abnormal immune response to brain tissue antigen in the syndrome of autism. Am J Psychiatry 139:1462–1465, 1982PubMedGoogle Scholar
  99. 99.
    Van Praag HM : CSF 5-HIAA and suicide in non-depressed schizophrenics. Lancet 2:977–978, 1983PubMedCrossRefGoogle Scholar
  100. 100.
    Stoff DM, Pollock L, Vitiello B, et al : Reduction of [3H]imipramine binding sites on platelets of conductdisordered children. Neuropsychopharmacology 1:55–62, 1987PubMedCrossRefGoogle Scholar
  101. 101.
    Modai I, Rotman A, Munitz H, et al : Serotonin uptake by blood platelets of acute schizophrenic patients. Psychopharmacology 64:193–195Google Scholar
  102. 102.
    Kaplan RD, Mann JJ : Altered platelet serotonin uptake kinetics in schizophrenia and depression. Life Sci 31:583–588, 1982PubMedCrossRefGoogle Scholar
  103. 103.
    Wood PL, Suranyi-Cadotte BE, Nair NPV, et al : Lack of association between [3H]imipramine binding sites and uptake of serotonin in control, depressed and schizophrenic patients. Neuropharmacology 22:1211–1214, 1983PubMedCrossRefGoogle Scholar
  104. 104.
    Meltzer HY, Arora RC, Baber R, et al : Serotonin uptake in blood platelets of psychiatric patients. Arch Gen Psychiatry 38:1322–1326, 1981PubMedCrossRefGoogle Scholar
  105. 105.
    Arora RC, Meltzer HY : Serotonin uptake by blood platelets of schizophrenic patients. Psychiatry Res 6:327–333, 1982PubMedCrossRefGoogle Scholar
  106. 106.
    Gentesch C, Lichtsteiner M, Gastpar M, et al : [3H]imipramine binding sites in platelets of hospitalized psychiatric patients. Psychiatry Res 14:177–187, 1985CrossRefGoogle Scholar
  107. 107.
    Kanof PD, Coccaro EF, Johns CA, et al : Platelet [3H]imipramine binding in psychiatric disorders. Biol Psychiatry 22:278–286, 1986CrossRefGoogle Scholar
  108. 108.
    Hanley HG, Stahl SM, Freedman DX : Hyperserotonemia and amine metabolites in autistic and retarded children. Arch Gen Psychiatry 34:521–531, 1977PubMedCrossRefGoogle Scholar
  109. 109.
    Young JG, Cohen DJ, Shaywitz BA, et al : Molecular pathology in early childhood psychoses, in Wing L. Wing J.K.(eds): Handbook of Psychiatry, Vol. 3: Psychoses of Uncertain Aetiology. Cambridge, Cambridge University Press, 1982, pp 229–235Google Scholar
  110. 110.
    Cohen DJ, Caparulo BK, Shaywitz BA, et al : Dopamine and serotonin metabolism in neuropsychiatrically disturbed children. Arch Gen Psychiatry 34:545–550, 1977PubMedCrossRefGoogle Scholar
  111. 111.
    Jensen JB, Realmuto GM, Garfinkel BD : The dexamethasone suppression test in infantile autism. J Am Acad Child Psychiatry 3:262–265, 1985Google Scholar
  112. 112.
    Young JG, Cohen DJ, Caparulo BK, et al : Decreased 24-hour urinary MHPG in childhood autism. Am J Psychiatry 136:1055–1057, 1979PubMedGoogle Scholar
  113. 113.
    Geller E, Ritvo ER, Freeman BJ, et al : Preliminary observations on the effect of fenfluramine on blood serotonin and symptoms in three autistic boys. N Engl J Med 307:165–168, 1982PubMedCrossRefGoogle Scholar
  114. 114.
    August GJ, Raz N, Baird TD : Effects of fenfluramine on behavioral cognitive and affective disturbances in autistic children. J Aut Dev Dis 15:97–107, 1985CrossRefGoogle Scholar
  115. 115.
    Yuwiler A, Ritvo ER, Geller E : Uptake and effects of serotonin from platelets of autistic and nonautistic children. J Autism Child Schiz 5:89–98, 1975CrossRefGoogle Scholar
  116. 116.
    Siva-Sanker DV : Uptake of 5-hydroxytryptamine by isolated platelets in childhood schizophrenia and autism. Neuropsychobiology 3:234–239, 1977CrossRefGoogle Scholar
  117. 117.
    Rotman A, Kaplan R, Szekely GA : Platelets uptake of serotonin in autistic and other psychotic children. Psychopharmacology 67:245–248, 1980PubMedCrossRefGoogle Scholar
  118. 118.
    Boullin Freeman BJ, Geller E, Ritvo E, et al : Toward the resolution on conflicting finding. J Autism Develop Dis 12:97–101, 1982CrossRefGoogle Scholar
  119. 119.
    Anderson GM, Minderaa RB, Van Benthen P-PG, et al : Platelet impramine binding in autistic subjects. Psychiatry Res 11:133–141, 1984PubMedCrossRefGoogle Scholar
  120. 120.
    Weizman A, Gonen N, Tyano S, et al : Platelet [3H]imipramine binding in autism and schizophrenia. Psychopharmacology 91:101–103, 1987PubMedCrossRefGoogle Scholar
  121. 121.
    Yehuda R, Meyer JS : A Role for serotonin in the hypothalamic-pituitary-adrenal response to insulin stress. Neuroendocrinology 38:25–32, 1984PubMedCrossRefGoogle Scholar
  122. 122.
    Field EJ, Caspary EA, Carnegie PR : Lymphocyte sensitization to basic protein of brain in malignant neoplasia: Experiments with serotonin and related compounds. Nature (Lond) 223:284–286, 1971CrossRefGoogle Scholar
  123. 123.
    Todd RD, Ciaranello RD : Demonstration of inter and intraspecies differences in serotonin binding sites by antibodies from an autistic child. Proc Natl Acad Sci USA 82:612–616, 1985PubMedCrossRefGoogle Scholar
  124. 124.
    Traskman-Benz L : CSF 5-HIAA and family history of psychiatric disorder. Am J Psychiatry 140:1257Google Scholar
  125. 125.
    Weizman A, Carel C, Tyano S, et al : Decreased high affinity [3H]imipramine binding in platelets in enuretic children and adolescent. Psychiatry Res 14:39–46, 1985PubMedCrossRefGoogle Scholar
  126. 126.
    Weizman R, Carmi M, Tyano S, et al : Reduced [3H]imipramine binding but unaltered [3H]serotonin uptake in platelets of adolescent enuretics. Psychiatry Res 19:37–42, 1986PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1990

Authors and Affiliations

  • Moshe Rehavi
    • 1
  • Ronit Weizman
    • 2
    • 3
  1. 1.Department of Physiology and Pharmacology, Sackler Faculty of MedicineTel Aviv UniversityTel AvivIsrael
  2. 2.Pediatric DepartmentHasharon HospitalPetah TiqvaIsrael
  3. 3.Sackler Faculty of MedicineTel Aviv UniversityTel AvivIsrael

Personalised recommendations